Publikationen 2026
- The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).
Griesshammer M, Al-Ali HK, Baerlocher GM, Döhner K, Koschmieder S, Kröger N, Petrides PE, Wolf D, Heidel FH. Int J Cancer. 2026 Oct 1;159(7):1633-1641. doi: 10.1002/ijc.70595. Epub 2026 Jun 21. PMID: 42324205 Free PMC article.
- Value of functional iron parameters in diagnostic re-assessment of MPN: refinement of iron-deficiency markers by zinc protoporphyrin (ZPP).
Manz K, Kobrosly M, Crodel CC, Al-Ali H, Isfort S, Kleppe D, Neubert M, Schnöder TM, Rogalski I, Jilg S, Stauch T, Hoffmann W, Krüger WH, Krönke J, Hochhaus A, Homann C, Heidel FH.
Ann Hematol. 2026 May 23;105(6):294. doi: 10.1007/s00277-026-07077-y.
PMID: 42176009 Free PMC article.
- MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.
Al-Ali HK, Heidel ST, Palandri F, Heidel FH.
Leukemia. 2026 Jun;40(6):1111-1121. doi: 10.1038/s41375-026-02975-6. Epub 2026 May 5.
PMID: 42086932 Free PMC article. Review.
- Patient-reported outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias.
Crodel CC, Kohnle C, Radsak MP, Nückel H, Jilg S, Hochhaus A, Heidel FH, Hübner J.
J Cancer Res Clin Oncol. 2026 Jan 20;152(1):41. doi: 10.1007/s00432-025-06421-5.
PMID: 41559233 Free PMC article.
- Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms.
Meyer R, Rodriguez MJ, Caduc M, Kricheldorf K, Begemann M, Kraft F, Spier I, Dey D, Güzel N, Becker K, Baumeister J, S de Toledo MA, Isfort S, Germing U, Aretz S, Brümmendorf TH, Kurth I, Elbracht M, Teichmann LL, Koschmieder S.
Blood Cancer J. 2026 Jan 5;16(1):2. doi: 10.1038/s41408-025-01433-3.
PMID: 41491914 Free PMC article. No abstract available.
- Integrin-dependence of extramedullary erythropoiesis in the spleen of Jak2-V617F positive myeloproliferative neoplasm in mice.
Baldauf CK, Poschmann L, Edelmann-Stephan B, Angenstein F, Haage TR, Bhuria V, Philipsen L, Berlin H, Dieterich DC, Böttcher M, Mougiakakos D, Schraven B, Fischer T.
Exp Hematol. 2026 Feb;154:105340. doi: 10.1016/j.exphem.2025.105340. Epub 2025 Dec 6.
PMID: 41360369
- [Myelofibrosis: watch and wait or treat?].
Griesshammer M.
Inn Med (Heidelb). 2026 May;67(5):588-594. doi: 10.1007/s00108-025-02021-0. Epub 2025 Dec 2.
PMID: 41329342 Review. German.
Publikationen 2025
- NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.
Koerber RM, Krollmann C, Cieslak K, Tregel E, Saenz ML, Brümmendorf TH, Koschmieder S, Griesshammer M, Gütgemann I, Baldauf CK, Fischer T, Brossart P, Kolbe CC, Latz E, Wolf D, Teichmann LL.
Nat Commun. 2025 Nov 26;16(1):10591. doi: 10.1038/s41467-025-65673-4.
PMID: 41298546 Free PMC article.
- Prediction of resistance to hydroxyurea therapy in patients with polycythemia vera: a machine learning study (PV-AIM) validated in a prospective interventional phase IV trial (HU-F-AIM).
Heidel FH, De Stefano V, Zaiss M, Kisro J, Gückel E, Großer S, Zuurman MW, Manz K, Bryan K, Afsharinejad A, Griesshammer M, Kiladjian JJ.
Leukemia. 2025 Jul;39(7):1692-1701. doi: 10.1038/s41375-025-02623-5. Epub 2025 Apr 25.
PMID: 40281326 Free PMC article. Clinical Trial.
- Mitigation of atrial fibrillation-related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG-MPN bioregistry.
Cho HR, Isfort S, Kricheldorf K, Stegelmann F, Klausmann M, Heidel FH, Griesshammer M, Schulz H, Hochhaus A, Göthert J, Schlag R, Hollburg W, Teichmann L, Sockel K, Wilop S, Gezer D, Kirschner M, Döhner K, Brümmendorf TH, Koschmieder S; German Study Group for Myeloproliferative Neoplasms (GSG‐MPN).
Hemasphere. 2025 Mar 17;9(3):e70090. doi: 10.1002/hem3.70090. eCollection 2025 Mar.
PMID: 40098896 Free PMC article. No abstract available.
- Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN).
Manz K, Heidel FH, Koschmieder S, Schlag R, Lipke J, Stegelmann F, Griesshammer M, Klausmann M, Crodel C, Hochhaus A, Schulz H, Göthert JR, Al-Ali H, Becker H, Reiter A, Beutel G, Kricheldorf K, Brümmendorf TH, Hoffmann W, Döhner K, Isfort S; German Study Group for Myeloproliferative Neoplasms (GSG-MPN).
Leukemia. 2025 Apr;39(4):864-875. doi: 10.1038/s41375-025-02524-7. Epub 2025 Feb 25.
PMID: 40000843 Free PMC article.
- Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria.
Koschmieder S, Panse J.
Hamostaseologie. 2025 Apr;45(2):166-174. doi: 10.1055/a-2482-3997. Epub 2025 Feb 3.
PMID: 39900098 Review.
- How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024.
Griesshammer M, Al-Ali HK, Eckardt JN, Fiegl M, Göthert J, Jentsch-Ullrich K, Koschmieder S, Kvasnicka HM, Reiter A, Schmidt B, Heidel FH.
Ann Hematol. 2025 Jan;104(1):295-306. doi: 10.1007/s00277-025-06191-7. Epub 2025 Jan 31.
PMID: 39888352 Free PMC article.
- Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alfa.
Kalmer M, Grasshoff M, Maié T, Pannen K, Toledo MAS, Vieri M, Olschok K, Lemanzyk R, Lazarevic J, Junge B, Baumeister J, Galauner A, Chapal Ilani N, Bar D, Colin E, Cheng M, Schifflers J, Kricheldorf K, Schemionek M, Brümmendorf TH, Weiskirchen R, Shlush L, Zenke M, Chatain N, Costa IG, Koschmieder S.
Blood Adv. 2025 Apr 22;9(8):1873-1887. doi: 10.1182/bloodadvances.2024012600.
PMID: 39874500 Free PMC article.
Publikationen 2024
- Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms.
Gorantla SP, Prince G, Osius J, Dinesh DC, Boddu V, Duyster J, von Bubnoff N.
Front Oncol. 2024 Jul 18;14:1430833. doi: 10.3389/fonc.2024.1430833. eCollection 2024.
PMID: 39091915 Free PMC article.
- Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms.
Zaninetti C, Vater L, Kaderali L, Crodel CC, Schnöder TM, Fuhrmann J, Swensson L, Wesche J, Freyer C, Greinacher A, Heidel FH.
Leukemia. 2024 Sep;38(9):2051-2058. doi: 10.1038/s41375-024-02346-z. Epub 2024 Jul 17.
PMID: 39020061 Free PMC article. No abstract available.
- Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group.
Koschmieder S, Bose P, Ellis MH, Gupta V, Kiladjian JJ, Mascarenhas J, Mathews V, Passamonti F, Harrison C.
Leukemia. 2024 Aug;38(8):1831-1838. doi: 10.1038/s41375-024-02330-7. Epub 2024 Jul 9.
PMID: 38982261 Free PMC article. No abstract available.
- FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH.
Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5.
PMID: 38967662 Free PMC article.
- Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms - a practical guide to WHO-HAEM5.
Kühn C, Hörst K, Kvasnicka HM, Hochhaus A, Reiter A.
Med Genet. 2024 Mar 6;36(1):31-38. doi: 10.1515/medgen-2024-2003. eCollection 2024 Apr.
PMID: 38835971 Free PMC article.
- Targeting metabolic dependencies in JAK2-V617F-driven MPNs.
Wolf D, Pircher A.
Blood Adv. 2024 May 14;8(9):2310-2311. doi: 10.1182/bloodadvances.2024012837.
PMID: 38743413 Free PMC article. No abstract available.
- Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores.
Kappenstein M, von Bubnoff N.
Cancers (Basel). 2024 Apr 5;16(7):1416. doi: 10.3390/cancers16071416.
PMID: 38611094 Free PMC article.
- Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry.
Bhuria V, Franz T, Baldauf C, Böttcher M, Chatain N, Koschmieder S, Brümmendorf TH, Mougiakakos D, Schraven B, Kahlfuß S, Fischer T.
Cell Commun Signal. 2024 Mar 21;22(1):186. doi: 10.1186/s12964-024-01530-z.
PMID: 38509561 Free PMC article.
- ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C.
Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4.
PMID: 38438627 Free PMC article.
- Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G.
Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4.
PMID: 38061384 Review.
- Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms.
Wille K, Deventer E, Sadjadian P, Becker T, Kolatzki V, Hünerbein K, Meixner R, Jiménez-Muñoz M, Fuchs C, Griesshammer M.
Hamostaseologie. 2024 Oct;44(5):386-392. doi: 10.1055/a-2159-8767. Epub 2023 Oct 9.
PMID: 37813367
Publikationen 2023
- Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms.
Holl K, Chatain N, Krapp S, Baumeister J, Maié T, Schmitz S, Scheufen A, Brock N, Koschmieder S, Moreno-Andrés D. Sci Rep. 2024 Feb 2;14(1):2810. doi: 10.1038/s41598-024-53240-8. PMID: 38308077 Free PMC article.
- Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche.
Flosdorf N, Böhnke J, de Toledo MAS, Lutterbach N, Lerma VG, Graßhoff M, Olschok K, Gupta S, Tharmapalan V, Schmitz S, Götz K, Schüler HM, Maurer A, Sontag S, Küstermann C, Seré K, Wagner W, Costa IG, Brümmendorf TH, Koschmieder S, Chatain N, Castilho M, Schneider RK, Zenke M. Stem Cell Reports. 2024 Jan 8:S2213-6711(23)00504-0. doi: 10.1016/j.stemcr.2023.12.011. Online ahead of print. PMID: 38278152 Free article.
- Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms.
Bermes M, Rodriguez MJ, de Toledo MAS, Ernst S, Müller-Newen G, Brümmendorf TH, Chatain N, Koschmieder S, Baumeister J. Int J Mol Sci. 2023 Dec 16;24(24):17560. doi: 10.3390/ijms242417560. PMID: 38139386 Free PMC article.
- Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms.
Pritchard JE, Pearce JE, Snoeren IAM, Fuchs SNR, Götz K, Peisker F, Wagner S, Benabid A, Lutterbach N, Klöker V, Nagai JS, Hannani MT, Galyga AK, Sistemich E, Banjanin B, Flosdorf N, Bindels E, Olschok K, Biaesch K, Chatain N, Bhagwat N, Dunbar A, Sarkis R, Naveiras O, Berres ML, Koschmieder S, Levine RL, Costa IG, Gleitz HFE, Kramann R, Schneider RK. Cell Rep. 2024 Jan 23;43(1):113608. doi: 10.1016/j.celrep.2023.113608. Epub 2023 Dec 20. PMID: 38117649 Free PMC article.
- A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance.
Gorantla SP, Mueller TA, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J. Mol Oncol. 2024 Feb;18(2):415-430. doi: 10.1002/1878-0261.13566. Epub 2023 Dec 20. PMID: 38104968 Free PMC article.
- Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4. PMID: 38061384 Review.
- The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling.
Olschok K, Altenburg B, de Toledo MAS, Maurer A, Abels A, Beier F, Gezer D, Isfort S, Paeschke K, Brümmendorf TH, Zenke M, Chatain N, Koschmieder S. Front Oncol. 2023 Oct 24;13:1277453. doi: 10.3389/fonc.2023.1277453. eCollection 2023. PMID: 37941547 Free PMC article.
- Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms.
Vieri M, Tharmapalan V, Kalmer M, Baumeister J, Nikolić M, Schnitker M, Kirschner M, Flosdorf N, de Toledo MAS, Zenke M, Koschmieder S, Brümmendorf TH, Beier F, Wagner W. Blood Cancer J. 2023 Nov 6;13(1):164. doi: 10.1038/s41408-023-00936-1. PMID: 37926720 Free PMC article. No abstract available.
- Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis.
Eisenach S, Zinke J, Brämer D, Hartinger S, Haferlach T, Kreipe HH, Hammersen J, Hamadanchi A, Otto S, Schulze PC, Bürckenmeyer F, Teichgräber U, Hochhaus A, Witte OW, Günther A, Schrenk KG. Ann Hematol. 2024 Jan;103(1):363-365. doi: 10.1007/s00277-023-05490-1. Epub 2023 Oct 16. PMID: 37843619 Free PMC article. No abstract available.
- Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms.
Wille K, Deventer E, Sadjadian P, Becker T, Kolatzki V, Hünerbein K, Meixner R, Jiménez-Muñoz M, Fuchs C, Griesshammer M. Hamostaseologie. 2023 Oct 9. doi: 10.1055/a-2159-8767. Online ahead of print. PMID: 37813367 Free article.
- Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study.
Manz K, Bahr J, Ittermann T, Döhner K, Koschmieder S, Brümmendorf TH, Griesshammer M, Nauck M, Völzke H, Heidel FH. Leukemia. 2023 Aug;37(8):1745-1749. doi: 10.1038/s41375-023-01943-8. Epub 2023 Jun 23. PMID: 37353711 Free PMC article. No abstract available.
- Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany.
Schmidt A, Bernhardt C, Bürkle D, Fries S, Hannig CV, Jentsch-Ullrich K, Josting A, Kreher S, Reiser M, Steinmetz HT, Tesch H, Terner S, Schulte A, Crodel CC, Palandri F, Heidel FH. J Cancer Res Clin Oncol. 2023 Aug;149(10):7197-7206. doi: 10.1007/s00432-023-04669-3. Epub 2023 Mar 8. PMID: 36884118 Free PMC article.
- Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study.
Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, Bonifacio M, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V. Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706. PMID: 37509367 Free PMC article.
- Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A, Rinke J, Crodel CC, Möbius S, Schäfer V, Heidel FH, Hochhaus A, Ernst T. Br J Haematol. 2023 Jul;202(2):308-317. doi: 10.1111/bjh.18834. Epub 2023 May 4. PMID: 37139709
- Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isession_id()ori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA. Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18. PMID: 36932983 Free article.
- Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib.
Palandri F, Elli EM, Auteri G, Bonifacio M, Benevolo G, Heidel FH, Paglia S, Trawinska MM, Bosi C, Rossi E, Tiribelli M, Tieghi A, Iurlo A, Polverelli N, Caocci G, Binotto G, Cavazzini F, Beggiato E, Cilloni D, Tatarelli C, Mendicino F, Miglino M, Bocchia M, Crugnola M, Mazzoni C, Romagnoli AD, Rindone G, Ceglie S, D'Addio A, Santoni E, Cattaneo D, Bartoletti D, Lemoli RM, Krampera M, Cuneo A, Semenzato GC, Latagliata R, Abruzzese E, Vianelli N, Cavo M, Andriani A, De Stefano V, Palumbo GA, Breccia M. Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6. PMID: 37137878 Free PMC article. No abstract available.
- Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. PMID: 36564535 Free PMC article. Clinical Trial.
- Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Stegelmann F, Teichmann LL, Heidel FH, Crodel CC, Ernst T, Kreil S, Reiter A, Otten S, Schauer S, Körber RM, Kricheldorf K, Isfort S, Döhner H, Brümmendorf TH, Griesshammer M, Döhner K, Koschmieder S. Leukemia. 2023 Apr;37(4):924-928. doi: 10.1038/s41375-023-01837-9. Epub 2023 Feb 24. PMID: 36828867; PMCID: PMC10079540
- Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gröschl B, Bachhuber P, Großer S, Pahl HL. Ann Hematol. 2023 Dec;102(12):3383-3399. doi: 10.1007/s00277-023-05458-1. Epub 2023 Oct 4. PMID: 37792065; PMCID: PMC10640411.
Publikationen 2022
- Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nałęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Am J Hematol. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27. PMID: 36111658 Free PMC article. No abstract available.
- BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ. Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901. Online ahead of print. PMID: 36416118 Free article. Review.
- Breakthrough infections in MPN-COVID vaccinated patients.
Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921 Free PMC article. No abstract available.
- Mast cells as a therapeutic target in myeloproliferative neoplasms.
Toledo MAS, Chatain N, Zenke M, Koschmieder S. Trends Mol Med. 2022 Nov;28(11):902-905. doi: 10.1016/j.molmed.2022.08.008. Epub 2022 Sep 2. PMID: 36064534
- Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.
Perram J, Ross DM, McLornan D, Gowin K, Kröger N, Gupta V, Lewis C, Gagelmann N, Hamad N. Am J Hematol. 2022 Nov;97(11):1464-1477. doi: 10.1002/ajh.26654. Epub 2022 Jul 19. PMID: 35802782 Free PMC article. Review.
- Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms. Kalmer M, Pannen K, Lemanzyk R, Wirths C, Baumeister J, Maurer A, Kricheldorf K, Schifflers J, Gezer D, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. Ann Hematol. 2022 Dec;101(12):2655-2663. doi: 10.1007/s00277-022-05000-9. Epub 2022 Oct 21. PMID: 36269400; PMCID: PMC9646600.
- German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. PMID: 36564535; PMCID: PMC9889492.
- Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Crodel CC, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, Ulshöfer T, Wunschel R, Palandri F, Heidel FH. J Cancer Res Clin Oncol. 2022 Oct;148(10):2693-2705. doi: 10.1007/s00432-021-03855-5. Epub 2021 Nov 22. PMID: 34807311 Free PMC article.
- Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms.
O'Hagan Henderson S, Frietsch JJ, Hilgendorf I, Hochhaus A, Köhne CH, Casper J. J Cancer Res Clin Oncol. 2022 Oct;148(10):2599-2609. doi: 10.1007/s00432-021-03836-8. Epub 2021 Oct 21. PMID: 34674031 Free PMC article.
- Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrenghea M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Blood Adv. 2022 Sep 13;6(17):5171-5183. doi: 10.1182/bloodadvances.2022007201. PMID: 35802458 Free PMC article.
- Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.
Ibarra J, Elbanna YA, Kurylowicz K, Ciboddo M, Greenbaum HS, Arellano NS, Rodriguez D, Evers M, Bock-Hughes A, Liu C, Smith Q, Lutze J, Baumeister J, Kalmer M, Olschok K, Nicholson B, Silva D, Maxwell L, Dowgielewicz J, Rumi E, Pietra D, Casetti IC, Catricala S, Koschmieder S, Gurbuxani S, Schneider RK, Oakes SA, Elf SE. Blood Cancer Discov. 2022 Jul 6;3(4):298-315. doi: 10.1158/2643-3230.BCD-21-0144. PMID: 35405004 Free PMC article.
- Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. PMID: 35597252 Clinical Trial.
- Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. PMID: 35358444 Review.
- Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
Bhuria V, Baldauf CK, Schraven B, Fischer T. Int J Mol Sci. 2022 Mar 16;23(6):3206. doi: 10.3390/ijms23063206. PMID: 35328626 Free PMC article. Review.
- [What's new in myeloproliferative neoplasia?].
Schmidt S, Wolf D. Dtsch Med Wochenschr. 2022 Mar;147(6):306-311. doi: 10.1055/a-1643-4357. Epub 2022 Mar 15. PMID: 35291035 German.
- Second versus first wave of COVID-19 in patients with MPN.
Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. Epub 2022 Jan 21. PMID: 35064223 Free PMC article. No abstract available.
- Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
Wille K, Huenerbein K, Jagenberg E, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Griesshammer M. Eur J Haematol. 2022 Feb;108(2):154-162. doi: 10.1111/ejh.13721. Epub 2021 Nov 10. PMID: 34719056
Publikationen 2021
- Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marín F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J. Leukemia. 2021 Oct;35(10):2989-2993.
- Anti-inflammatory treatment in MPN: Targeting TNFα-receptor 1 (TNFR1) and TNFR2 in JAK2-V617F induced disease. Müller P, Baldauf CK, Haage TR, Waldleben AM, Richter F, Pfizenmaier K, Fischer T. Blood Adv. 2021 Sep 30:bloodadvances.2021004438. doi: 10.1182/bloodadvances.2021004438. Epub ahead of print. PMID: 34592754.
- Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Schmidt S, Daniliants D, Hiller E, Gunsilius E, Wolf D, Feistritzer C. Blood Adv. 2021 Sep 28;5(18):3515-3527.
- Anti-IL-6 cytokine treatment has no impact on elevated hematocrit and splenomegaly in a polycythemia vera mouse model. Baldauf CK, Müller P, Haage TR, Adam-Frey S, Lokau J, Garbers C, Fischer T. Blood Adv. 2021 Sep 24:bloodadvances.2021004379. doi: 10.1182/bloodadvances.2021004379. Epub ahead of print. PMID: 34559181.
- Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms. Elbracht M, Meyer R, Kricheldorf K, Gezer D, Thomas E, Betz B, Kurth I, Teichmann LL, Brümmendorf TH, Germing U, Isfort S, Koschmieder S. Blood Adv. 2021 Sep 14;5(17):3373-3376.
- The EHA Research Roadmap: Malignant Myeloid Diseases. Döhner H, Malcovati L, Ossenkoppele GJ, Hochhaus A, Maria Vannucchi A, Bullinger L, Cervantes F, Craddock C, de Witte T, Döhner K, Dombret H, Fenaux P, Geissler J, Germing U, Guilhot F, Harrison C, Hellström-Lindberg E, Passamonti F, Sierra J, Skoda R, Wierzbowska A. Hemasphere. 2021 Aug 26;5(9):e635.
- The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. O'Hagan Henderson S, Glaser A, Frietsch JJ, Hochhaus A, Hilgendorf I. Ann Hematol. 2021 Sep 1. doi: 10.1007/s00277-021-04655-0. Epub ahead of print. PMID: 34471943.
- Unmet clinical needs in the management of CALR- mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Alvarez-Larrán A, Sant'Antonio E, Harrison C, Kiladjian JJ, Griesshammer M, Mesa R, Ianotto JC, Palandri F, Hernández-Boluda JC, Birgegård G, Nangalia J, Koschmieder S, Rumi E, Barbui T. Lancet Haematol. 2021 Sep;8(9):e658-e665.
- NK Cells in Myeloproliferative Neoplasms (MPN). Naismith E, Steichen J, Sopper S, Wolf D. Cancers (Basel). 2021 Aug 31;13(17):4400.
- The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN. Tillmann S, Olschok K, Schröder SK, Bütow M, Baumeister J, Kalmer M, Preußger V, Weinbergerova B, Kricheldorf K, Mayer J, Kubesova B, Racil Z, Wessiepe M, Eschweiler J, Isfort S, Brümmendorf TH, Becker W, Schemionek M, Weiskirchen R, Koschmieder S, Chatain N. Cancers (Basel). 2021 Aug 21;13(16):4210.
- Early and late stage MPN patients show distinct gene expression profiles in CD34 + cells Baumeister J, Maié T, Chatain N, Gan L, Weinbergerova B, de Toledo MAS, Eschweiler J, Maurer A, Mayer J, Kubesova B, Racil Z, Schuppert A, Costa I, Koschmieder S, Brümmendorf TH, Gezer D. Ann Hematol. 2021 Aug 14. doi: 10.1007/s00277-021-04615-8. Epub ahead of print. PMID: 34390367.
- Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M, Pahl HL, Lang F, Kirschner M, Isfort S, Brümmendorf TH, Döhner K, Koschmieder S. Cancers (Basel). 2021 Aug 13;13(16):4086.
- Pacritinib protects dendritic cells more efficiently than ruxolitinib. Heine A, Wolf AM, Schlaweck S, Daecke SN, Brossart P, Wolf D. Exp Hematol. 2021 Aug;100:37-40.
- Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. Huenerbein K, Sadjadian P, Becker T, Kolatzki V, Deventer E, Engelhardt C, Griesshammer M, Wille K. Ann Hematol. 2021 Aug;100(8):2015-2022.
- Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. Passamonti F, Gupta V, Martino B, Foltz L, Zaritskey A, Al-Ali HK, Tavares R, Maffioli M, Raanani P, Giraldo P, Griesshammer M, Guglielmelli P, Bouard C, Paley C, Tiwari R, Vannucchi AM. Hematol Oncol. 2021 Jul 5.
- A review of hydroxyurea-related cutaneous adverse events. Griesshammer M, Wille K, Sadjadian P, Stegelmann F, Döhner K. Expert Opin Drug Saf. 2021 Jun 28:1-7.
- Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. Kricheldorf K, Döhner K, Stegelmann F, Jost PJ, Lang F, Radsak M, Hansen R, Heuer V, Röhrig R, Brümmendorf TH, Koschmieder S, Isfort S. Leuk Res. 2021 Jun 16;110:106646.
- Long-term follow-up of recovered MPN patients with COVID-19. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Blood Cancer J. 2021 Jun 16;11(6):115.
- JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Rao TN, Hansen N, Stetka J, Luque Paz D, Kalmer M, Hilfiker J, Endele M, Ahmed N, Kubovcakova L, Rybarikova M, Hao-Shen H, Geier F, Beisel C, Dirnhofer S, Schroeder T, Brümmendorf TH, Wolf D, Koschmieder S, Skoda RC. Blood. 2021 Apr 22;137(16):2139-2151.
- Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Büsche G, Kreipe H, Gütgemann I, Krebs P, Banz Y, Boor P, Tai EW, Brümmendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK. Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8.
- Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Leuk Lymphoma. 2021 Apr;62(4):918-926.
- Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Rambaldi A, Iurlo A, Vannucchi AM, Martino B, Guarini A, Ruggeri M, von Bubnoff N, De Muro M, McMullin MF, Luciani S, Martinelli V, Nogai A, Rosti V, Ricco A, Bettica P, Manzoni S, Di Tollo S. Blood Cancer J. 2021 Mar 6;11(3):53.
- Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Handlos Grauslund J, Holmström MO, Jørgensen NG, Klausen U, Weis-Banke SE, El Fassi D, Schöllkopf C, Clausen MB, Gjerdrum LMR, Breinholt MF, Kjeldsen JW, Hansen M, Koschmieder S, Chatain N, Novotny GW, Petersen J, Kjær L, Skov V, Met Ö, Svane IM, Hasselbalch HC, Andersen MH. Front Oncol. 2021 Feb 26;11:637420.
- Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Blood Cancer J. 2021 Feb 4;11(2):21.
- Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. Ernst P, Heidel FH. Cancers (Basel). 2021 Feb 4;13(4):612.
- High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Leukemia. 2021 Feb;35(2):485-493.
- A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs. Schnoeder TM, Perner F, Heidel FH. Mol Cell Oncol. 2021 Jan 30;8(2):1871172.
- Austrian recommendations for the management of essential thrombocythemia. Buxhofer-Ausch V, Heibl S, Sliwa T, Beham-Schmid C, Wolf D, Geissler K, Krauth MT, Krippl P, Petzer A, Wölfler A, Melchardt T, Gisslinger H. Wien Klin Wochenschr. 2021 Jan;133(1-2):52-61.
- Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion- dependence and correlate with response to pomalidomide. Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ; RESUME trialists. Leukemia. 2021 Apr;35(4):1197-1202.
- Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, Becker T, Kolatzki V, Döhner H, Stadler R; German Study Group-MPN, Döhner K, Griesshammer M. Leukemia. 2021 Feb;35(2):628-631.
- Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm. Molitor DCA, Boor P, Buness A, Schneider RK, Teichmann LL, Körber RM, Horvath GL, Koschmieder S, Gütgemann I. Ann Hematol. 2021 Jan;100(1):97-104.
Publikationen 2020
- Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Leukemia. 2020 Nov;34(11):3106. doi: 10.1038/s41375-020-0970-2. Erratum for: Leukemia. 2020 Jul;34(7):1949-1953. PMID: 32651539; PMCID: PMC7962558.
- German Study Group MPN, GSG-MPN. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, Griesshammer M, Wille K;. J Cancer Res Clin Oncol. 2021 May;147(5):1481-1491. doi: 10.1007/s00432-020-03430-4. Epub 2020 Nov 2. PMID: 33140210.
- Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Nature. 2020 Dec;588(7836):157-163.
- Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Chase A, Score J, Lin F, Bryant C, Waghorn K, Yapp S, Carreno-Tarragona G, Aranaz P, Villasante A, Ernst T, Cross NCP. Leukemia. 2020 Dec;34(12):3206-3214.
- EZH2 in Myeloid Malignancies. Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. Cells. 2020 Jul 8;9(7):1639.
- Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Javorniczky NR, Wehrle J, Ihorst G, Hupfer V, Aumann K, Pfeifer D, Niemöller C, Bleul S, Pantic M, Werner M, Duyster J, Finke J, Engelhardt M, von Bubnoff N, Waller CF, Pahl HL, Becker H. Leuk Res. 2020 Sep 15;98:106454.
- Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. Sadjadian P, Wille K, Griesshammer M. Cancers (Basel). 2020 Oct 26;12(11):E3132.
- Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Chatain N, Koschmieder S, Jost E. Cancers (Basel). 2020 Aug 12;12(8):E2250.
- Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Leukemia. 2020 Jul;34(7):1949-1953. Erratum in: Leukemia. 2020 Jul 10;: PMID: 32474573; PMCID: PMC7261209.
- Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, Storch N, Haferlach T, Horny HP, Fabarius A, Haferlach C, Burchert A, Hofmann WK, Cross NCP, Hochhaus A, Reiter A, Metzgeroth G. Am J Hematol. 2020 Jul;95(7):824-833.
- Role of inflammation in the biology of myeloproliferative neoplasms. Koschmieder S, Chatain N. Blood Rev. 2020 Jul;42:100711
- Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Gupta V, Wolleschak D, Hasselbalch H, Vannucchi AM, Koschmieder S, Cervantes F, Li Y, Dong T, Wroclawska M, Bharathy S, Harrison C. Blood Adv. 2020 Jul 14;4(13):3063-3071.
- Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Br J Haematol. 2020 Jun;189(5):888-903.
- Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW.Leukemia. 2020 Apr;34(4):1075-1089.
- Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Baumeister J, Chatain N, Hubrich A, Maié T, Costa IG, Denecke B, Han L, Küstermann C, Sontag S, Seré K, Strathmann K, Zenke M, Schuppert A, Brümmendorf TH, Kranc KR, Koschmieder S, Gezer D. Leukemia. 2020 Apr;34(4):1062-1074.
- Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Barbui T, Ghirardi A, Vannucchi AM, Marchetti M, De Stefano V; MPN-K authors. Leukemia. 2020 Apr;34(4):1208-1209.
- Second cancers in MPN: survival analysis from an international study. Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Am J Hematol. 2020 Mar;95(3):295-301.
- Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Lancet Haematol. 2020 Mar;7(3):e226-e237.
- How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms. Koschmieder S. Hamostaseologie. 2020 Feb;40(1):47-53.
- Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson CIM, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Blood. 2020 Jan 30;135(5):381-386.